-
Electronic (PDF)
-
Site License
-
Enterprisewide
Recentin (Ovarian Cancer) - Analysis And Forecasts to 2020
GlobalData, September 2011, Pages: 31
Recentin (Ovarian Cancer) – Analysis And Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “Recentin (Ovarian Cancer) – Analysis and Forecasts to 2020” provides Recentin sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, and EU5 (six major markets)
- Analysis and review of Recentin including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Recentin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2016-2020 for Recentin in the six major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
Recentin, Ovarian Cancer, cediranib, targeted therapy , AstraZeneca, Phase III, Yondelis, Avastin, MORAb 003, Vascular Endothelial Growth Factor , VEGF
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Ovarian Cancer
2.2 Ovarian Cancer Market
2.3 Epidemiology
2.4 Etiology
2.4.1 Age
2.4.2 Inherited Gene Mutations
2.4.3 A Previous Cancer Diagnosis
2.4.4 Early Menstruation or Late menopause
2.4.5 Family History of Ovarian Cancer
2.5 GlobalData Market Forecasts Report Guidance
3 Ovarian Cancer: Market Characterization
3.1 Ovarian Cancer Market
3.2 Ovarian Cancer Market Forecasts and CAGR
3.3 Drivers for Ovarian Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality Rate
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer
3.3.4 Emergence of Targeted Therapy Drugs
3.3.5 Recurrence of Tumor
3.3.6 Low Initial Diagnosis Rate
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer
5 Recentin (cediranib)
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of Recentin
5.4.1 Limited Treatment Options
5.4.2 Oral Administration
5.4.3 Low Relative Efficacy
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Intensity of Competition
5.6 Sales Forecasts
5.6.1 Target Patient Pool of Recentin
5.6.2 Dosing
5.6.3 Market Penetration
5.6.4 Annual Cost of Therapy
5.6.5 Sales Forecasts of Recentin
6 Ovarian Cancer Market: Appendix
6.1 Market Definitions
6.2 Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
1.1 List of Tables
Table 1: Ovarian Cancer, Incidences and Mortality, 2008–2030
Table 2: Detailed TNM Classification
Table 3: Drug Risk Benefit Score of Recentin
Table 4: Recentin, Ovarian Cancer, Global, Annual Cost of Therapy ($), 2016
Table 5: Recentin, Ovarian Cancer, US and EU–5, Sales Forecasts ($m), 2016–2020
Table 6: Recentin, Ovarian Cancer, The US, Sales Forecasts ($m), 2017–2020
Table 7: Recentin, Ovarian Cancer, UK, Sales Forecasts ($m), 2016–2020
Table 8: Recentin, Ovarian Cancer, France, Sales Forecasts ($m), 2016–2020
Table 9: Recentin, Ovarian Cancer, Germany, Sales Forecasts ($m), 2016–2020
Table 10: Recentin, Ovarian Cancer, Italy, Sales Forecasts ($m), 2016–2020
Table 11: Recentin, Ovarian Cancer, Spain, Sales Forecasts ($m), 2016–2020
1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030
Figure 4: Oncology, Worldwide, Incidence (million), 2008-2030
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030
Figure 6: Broad Classification of Ovarian Cancer
Figure 7: Classification of Ovarian Cancer
Figure 8: Drug Model Diagram of Recentin
Figure 9: Recentin, Ovarian Cancer, US and EU–5, Sales Forecasts ($m), 2016–2020
Figure 10: Recentin, Ovarian Cancer, The US, Sales Forecasts ($m), 2017–2020
Figure 11: Recentin, Ovarian Cancer, UK, Sales Forecasts ($m), 2016–2020
Figure 12: Recentin, Ovarian Cancer, France, Sales Forecasts ($m), 2016–2020
Figure 13: Recentin, Ovarian Cancer, Germany, Sales Forecasts ($m), 2016–2020
Figure 14: Recentin, Ovarian Cancer, Italy, Sales Forecasts ($m), 2016–2020
Figure 15: Recentin, Ovarian Cancer, Spain, Sales Forecasts ($m), 2016–2020
Figure 16: Recentin, Ovarian Cancer, US and EU–5, Sales Distribution (%), 2020
Figure 17: Patients Approved for the Drug
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
